<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003353.pub2" GROUP_ID="UPPERGI" ID="372000111615535197" MERGED_FROM="" MODIFIED="2014-11-26 14:32:28 +0000" MODIFIED_BY="Karin Dearness" REVIEW_NO="21" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2014-11-26 14:32:28 +0000" MODIFIED_BY="Karin Dearness">
<TITLE MODIFIED="2014-11-11 04:54:46 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Suggest: Metoclopramide for transpyloric placement of migration of naso-enteral feeding tubes Elizabeth Royle notes that 'Metoclopramide for transplyloric migration in placement of naso-enteral feeding tubes' might be better.&lt;/p&gt;" NOTES_MODIFIED="2014-11-11 04:54:46 -0500" NOTES_MODIFIED_BY="[Empty name]">Metoclopramide for post-pyloric placement of naso-enteral feeding tubes</TITLE>
<CONTACT MODIFIED="2014-11-26 14:32:28 +0000" MODIFIED_BY="Karin Dearness"><PERSON ID="16708" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cristiane Costa Reis</FIRST_NAME><MIDDLE_INITIALS>da</MIDDLE_INITIALS><LAST_NAME>Silva</LAST_NAME><EMAIL_1>cristianereisfb@gmail.com</EMAIL_1><EMAIL_2>cristiane.reis@fasm.edu.br</EMAIL_2><ADDRESS><ORGANISATION/><ADDRESS_1>Joaquim Calado 120</ADDRESS_1><ADDRESS_2>Federação</ADDRESS_2><CITY>Salvador</CITY><ZIP>40230093</ZIP><REGION>Bahia</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-11-26 14:32:28 +0000" MODIFIED_BY="Karin Dearness"><PERSON ID="16708" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cristiane Costa Reis</FIRST_NAME><MIDDLE_INITIALS>da</MIDDLE_INITIALS><LAST_NAME>Silva</LAST_NAME><EMAIL_1>cristianereisfb@gmail.com</EMAIL_1><EMAIL_2>cristiane.reis@fasm.edu.br</EMAIL_2><ADDRESS><ORGANISATION/><ADDRESS_1>Joaquim Calado 120</ADDRESS_1><ADDRESS_2>Federação</ADDRESS_2><CITY>Salvador</CITY><ZIP>40230093</ZIP><REGION>Bahia</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="828110F882E26AA200E51E67E25FC1CF" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cathy</FIRST_NAME><LAST_NAME>Bennett</LAST_NAME><POSITION>Visiting Professor</POSITION><EMAIL_1>info@systematicresearch.co.uk</EMAIL_1><EMAIL_2>info@systematicresearch.co.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Technology Enabled Health Research (CTEHR)</DEPARTMENT><ORGANISATION>Coventry University</ORGANISATION><ADDRESS_1>Priory Street</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV1 5FB</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="5179" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Humberto</FIRST_NAME><LAST_NAME>Saconato</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>hsaconato@gmail.com</EMAIL_1><EMAIL_2>hsaconato@yahoo.com.br</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>Santa Casa de Campo Mourão</ORGANISATION><ADDRESS_1>BR 158 Saída para Peabiru, 2761</ADDRESS_1><CITY>Campo Mourão</CITY><ZIP>87309-650</ZIP><REGION>Campo Mourão</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 44 3523-3163</PHONE_1><PHONE_2>+55 44 8825-4130</PHONE_2><FAX_1>+55 11 5575-2970</FAX_1><FAX_2>+55 44 3523-3163</FAX_2></ADDRESS></PERSON><PERSON ID="5183" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Álvaro</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Atallah</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Director of Brazilian Cochrane Centre</POSITION><EMAIL_1>atallahmbe@uol.com.br</EMAIL_1><EMAIL_2>alvaro.atallah@gmail.com</EMAIL_2><URL>www.centrocochranedobrasil.org</URL><MOBILE_PHONE>+55 11 98173 0404</MOBILE_PHONE><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION><ADDRESS_1>R. Borges Lagoa, 564 cj 63</ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04038-000</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5571 4721</PHONE_1><PHONE_2>+55 11 5575 2970</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-11-26 09:30:58 -0500" MODIFIED_BY="Karin Dearness">
<UP_TO_DATE>
<DATE DAY="21" MONTH="10" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="10" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="10" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-11-20 11:14:20 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-11-20 11:14:20 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>Literature search was re-run, with 58 new studies identified, no new studies fitted the inclusion criteria.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-11 10:57:50 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>Updated format of review to current standards, conclusions unchanged.</P>
<P>New author (CB) added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-02-18 10:17:50 -0500" MODIFIED_BY="Karin L Dearness">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-02-18 10:17:50 -0500" MODIFIED_BY="Karin L Dearness">
<DATE DAY="10" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-12-10 06:07:53 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-10 06:07:38 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="14" MONTH="10" YEAR="2005"/>
<DESCRIPTION>
<P>New studies sought but none found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-12-10 06:07:35 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="23" MONTH="8" YEAR="2004"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="5" MONTH="8" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-26 09:33:18 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-11-24 07:59:46 -0500" MODIFIED_BY="Cathy Bennett">
<TITLE MODIFIED="2014-10-29 16:14:56 -0400" MODIFIED_BY="[Empty name]">Metoclopramide for accurate placement of naso-enteral feeding tube</TITLE>
<SUMMARY_BODY MODIFIED="2014-11-24 07:59:46 -0500" MODIFIED_BY="Cathy Bennett">
<P>
<B>Background</B>
</P>
<P>When a person is unwell and is unable to eat (or to eat enough), the lack of nutrition can be a serious obstacle to recovery. In these circumstances, feeding through a feeding tube that enters through the nose and passes through the stomach to the small intestine beyond (a post-pyloric naso-enteral feeding tube), is an option.</P>
<P>
<B>Review question</B>
</P>
<P>Once the feeding tube has entered the digestive system, placing the feeding tube into the small intestine rather than the stomach is difficult. Metoclopramide (which is also an anti-sickness medication), increases the rate at which the stomach empties, and has tested as a therapy to determine whether it assists with placement of post-pyloric naso-enteral feeding tubes.</P>
<P>Use of metoclopramide is controversial, as it may cause harms (adverse reactions), which may be serious and may include an irreversible neurological condition that can be caused by prolonged use, or high doses of metoclopramide.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We originally searched for clinical trials in 2002; and again in 2008 and 2014. We identified four studies that investigated the use of metoclopramide in placement of post-pyloric naso-enteral feeding tubes. The trials included a total of 204 adult participants; 108 participants were treated with metoclopramide, and 96 were given a placebo or no treatment. All four studies were done in hospitals in the USA. The number of participants included in the trials varied from 105 to 10.</P>
<P>The trials were all performed before 1995. They were all small, and examined two different doses of metoclopramide (10 mg and 20 mg), delivered in two different ways (intravenously, and injected into muscle). The way in which they were conducted and reported was poor.</P>
<P>
<B>Key results</B>
</P>
<P>Analysis of the four trials revealed that metoclopramide did not have a clear beneficial on the placement of post-pyloric naso-enteral feeding tubes. No harms (adverse reactions) were reported, though it was not clear how thoroughly the people running the trials recorded them. No costs of treatment were reported.</P>
<P>
<B>Quality of the evidence</B>
<BR/>
</P>
<P>The quality of the evidence is very low. The four trials were too small to identify any effect clearly; they also used different doses of metoclopramide, (tested against placebo or no treatment). It is unlikely that further studies will be performed to establish whether metoclopramide is helpful in placement of post-pyloric naso-enteral feeding tubes.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<ABS_BACKGROUND MODIFIED="2014-11-24 08:02:10 -0500" MODIFIED_BY="Cathy Bennett">
<P>Enteral nutrition by feeding tube is a common and efficient method of providing nutritional support to prevent malnutrition in hospitalised patients who have adequate gastrointestinal function but who are unable to eat. Gastric feeding may be associated with higher rates of food aspiration and pneumonia than post-pyloric naso-enteral tubes. Thus, enteral feeding tubes are placed directly into the small intestine rather than the stomach, and the use of metoclopramide, a prokinetic agent, has been recommended to achieve post-pyloric placement, but its efficacy is controversial. Moreover, metoclopramide may include adverse reactions, which with high doses or prolonged use may be serious and irreversible. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>To determine the effect of intravenous metoclopramide on post-pyloric placement of the naso-enteral tube in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<P>Trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 10) which includes the CUGPD group's specialised register of trials, MEDLINE (1996 to 21 October 2014), EMBASE (1988 to 21 October 2014), LILACS (2005 to 21 October 2014)   We did not confine our search to English language publications. Searches in all databases were updated originally in January 2005, then in November 2008 and again in October 2014. No new studies were found in 2008 or in 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>We selected randomised controlled trials of adults needing enteral nutrition, who received intravenous or intramuscular metoclopramide to aid placement of transpyloric naso-enteral feeding tubes, compared to placebo or no intervention.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-10-29 16:50:01 -0400" MODIFIED_BY="[Empty name]">
<P>We used standard methodological procedures expected by The Cochrane Collaboration. All analyses were performed according to the intention-to-treat method. We present risk ratios (RR) with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-11-24 06:26:06 -0500" MODIFIED_BY="Cathy Bennett">
<P>Four studies, with a total of 204 participants were included and analysed. The trials compared metoclopramide with placebo (two trials) or with no intervention (two trials). Metoclopramide was investigated at doses of 10 mg (two trials) and 20 mg (two trials). There was no statistically significant difference between metoclopramide versus placebo or no intervention administered to promote tube placement (RR 0.82, 95% CI 0.61 to 1.10). Metoclopramide at doses of 10 mg (RR 0.82, 95% CI 0.60 to 1.11) and 20 mg (RR 0.62, 95% CI 0.15 to 2.62) were equally ineffective in facilitating post-pyloric intubation when compared with placebo or no intervention.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>In this review, we found only four studies that fitted our inclusion criteria. These were small, underpowered studies, in which metoclopramide was given at doses of 10 mg and 20 mg. Our analysis showed that metoclopramide did not assist post-pyloric placement of naso-enteral feeding tubes.</P>
<P>Ideally randomised clinical trials should be performed that have a significant sample size, administering metoclopramide against control, however, given the lack of efficacy revealed by this review it is unlikely that further studies will be performed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-26 09:33:18 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-11-24 12:18:16 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-11-24 12:17:26 -0500" MODIFIED_BY="[Empty name]">
<P>Enteral nutrition by feeding tube is a common and efficient method of providing nutritional support to prevent malnutrition in hospitalised patients who have adequate gastrointestinal function but who are unable to eat. Post-pyloric naso-enteral feeding tubes, that enter through the nasal passages and deliver food directly to the duodenum or jejunum, have lower incidence of complications compared to naso-gastric tubes - which deliver food to the stomach - because of their lower rate of gastroesophageal reflux, regurgitation, excessive salivation and irritation of the mucosas. This can be uncomfortable for the patient and also increases the risk of aspiration of food, which can lead to pneumonia. Post-pyloric feeding tube (catheter) placement is not straightforward, but is easier when using manoeuvres such as putting patients in the right-sided lateral position or stimulating them to walk. A stimulating gastric motility drug such as metoclopramide has been used as an auxiliary therapy to promote tube placement. Metoclopramide could also be applied in cases where the tube has successfully entered the digestive system through the throat and into the oesophagus (gullet) and stomach but migration of the tube through the pyloric sphincter (between the stomach and duodenum) is delayed (<LINK REF="REF-Troncon-2000" TYPE="REFERENCE">Troncon 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-11-24 12:18:16 -0500" MODIFIED_BY="[Empty name]">
<P>Metoclopramide is a gastrointestinal stimulant and anti-sickness (antiemetic) drug, which increases the gastric emptiness (<LINK REF="REF-Sumner-1986" TYPE="REFERENCE">Sumner 1986</LINK>). Metoclopramide has a local stimulating effect on gastric motility and causes the acceleration of gastric emptiness without any concomitant secretion of gastric acid. It is useful for treating gastroesophageal reflux and in disorders of gastric emptiness, but not in the paralytic ileum (<LINK REF="REF-Rang-1997" TYPE="REFERENCE">Rang 1997</LINK>).</P>
<P>One study has demonstrated that metoclopramide is useful in post-pyloric feeding tube placement in diabetic patients, increasing the frequency of successful post-pyloric intubation in these patients, but not in non-diabetic patients (<LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>). In another small study comparing placebo, metoclopramide treatment after tube placement, and metoclopramide treatment before tube placement, duodenal intubation occurred in 90% of patients who received metoclopramide before feeding tube introduction (<LINK REF="STD-Kalfarentzos-1987" TYPE="STUDY">Kalfarentzos 1987</LINK>). Metoclopramide is not effective when administered after tube introduction (<LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>). Additionally, metoclopramide may be associated with adverse events, for example, <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK> indicated that restlessness, drowsiness, agitation, rashes (urticaria) and occasional drug-induced movement disorders (extrapyramidal reactions) may occur when using metoclopramide at a dose of 20 mg.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-11-11 05:01:57 -0500" MODIFIED_BY="[Empty name]">
<P>As there is no systematic review evaluating the effectiveness of parenteral metoclopramide, we will try to answer the following question: is metoclopramide effective and safe for the post-pyloric placement of naso-enteral feeding tubes?</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-11-21 14:14:48 -0500" MODIFIED_BY="[Empty name]">
<P>To determine the effect of intravenous metoclopramide on post-pyloric placement of the naso-enteral tube in adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-24 08:07:38 -0500" MODIFIED_BY="Cathy Bennett">
<SELECTION_CRITERIA MODIFIED="2014-11-24 08:07:38 -0500" MODIFIED_BY="Cathy Bennett">
<CRIT_STUDIES MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing metoclopramide with placebo or no intervention for the placement of naso-enteral tubes. RCTs were included irrespective of publication status, language or blinding.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>Participants were all adults (over 18 years of age) receiving parenteral metoclopramide for introduction of enteral feeding tube.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-04-28 10:48:33 -0400" MODIFIED_BY="Cathy Bennett">
<P>Metoclopramide against placebo or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-11-24 08:07:38 -0500" MODIFIED_BY="Cathy Bennett">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-11-11 04:55:27 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>Success rate of post-pyloric placement of the naso-enteral feeding tube.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-11-24 08:07:38 -0500" MODIFIED_BY="Cathy Bennett">
<P>Adverse reactions including:</P>
<UL>
<LI>depression;</LI>
<LI>high blood pressure;</LI>
<LI>decrease of libido;</LI>
<LI>headache;</LI>
<LI>skin rash;</LI>
<LI>fatigue;</LI>
<LI>fever;</LI>
<LI>hyperactivity;</LI>
<LI>insomnia;</LI>
<LI>nausea;</LI>
<LI>sedation;</LI>
<LI>tremor and agitation in the hand;</LI>
<LI>dyslalia (speech difficulties);</LI>
<LI>dysphagia (swallowing problems).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<ELECTRONIC_SEARCHES MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<P>Trials were identified by searching:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 10; <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), which includes the CUGPD group's specialised register of trials;</LI>
<LI>MEDLINE (1996 to 21 October 2014; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>EMBASE (1988 to 21 October 2014; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI>
<LI>LILACS (2005 to 21 October 2014; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
<P>We did not confine our search to English language publications. Searches in all databases were updated in January 2005 and updated again in November 2008 and October 2014. No new studies were found by the searches in 2008, or in October 2014.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-11-21 14:15:37 -0500" MODIFIED_BY="[Empty name]">
<P>We handsearched reference lists from trials selected by electronic searches to identify further relevant trials.</P>
<P>In addition, we contacted members of the Cochrane Upper Gastrointestinal and Pancreatic Diseases (UGPD) review Group, experts in the field, editors of relevant journals and pharmaceutical companies involved in the production of metoclopramide to ask them to supply details of any outstanding clinical trials and relevant unpublished materials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>Two reviewers (CCRS and HS) applied the inclusion criteria to all potential randomised studies. For this updated review CB and CCRS reviewed the results of the updated searches and applied the inclusion criteria to all potential randomised studies.</P>
<P>Review authors were not blinded to the reporting of authors' names, journals, date of publication, sources of financial support or results.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>Two reviewers (CCRS, HS with CB) independently extracted the following pre-specified characteristics of all included RCTs. In case of discrepancy, the opinion of a fourth reviewer was sought in order to reach a consensus. We extracted data on the: methods, including diagnostic procedure, baseline evaluation of the adequate primary outcomes, and reliability of the outcome measures, complete follow-up; the participants, including age, indication for naso-enteral intubation, number of randomised patients; the intervention dosage, co-intervention in the control group, and route and timing of administration; and outcomes, that is success rate of post-pyloric placement into the duodenum and adverse reactions.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>In this updated review, we independently assessed the risk of bias of the included studies using the risk of bias assessment tool described in Chapter 8 of the<I> Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We compared the evaluations, and discussed and resolved any inconsistencies between the review authors' decisions.</P>
<P>We rated the following domains separately for each of the included studies as 'low risk of bias', 'high risk of bias', and 'unclear' when the risk of bias was uncertain or unknown: </P>
<UL>
<LI>generation of allocation sequence ('sequence generation');</LI>
<LI>concealment of allocation ('allocation concealment');</LI>
<LI>prevention of knowledge of the allocated interventions during the study ('blinding');</LI>
<LI>methods used to address incomplete outcome data;</LI>
<LI>selective outcome reporting;</LI>
<LI>other sources of bias that could put a study at high risk of bias, including whether a calculation of sample size was carried out.</LI>
</UL>
<P>These assessments are reported in the 'Risk of bias' table for each individual study in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' section of the review, and in the '<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>' section of this review.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>We presented dichotomous outcomes data as risk ratios (RR) with their associated 95% confidence intervals; these were analysed in Review Manager 5.3 using the Mantel-Haenszel test and a random-effects model (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), unless stated otherwise.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>We did not expect any cross-over trials, as it is unlikely that the participants would be crossed-over to receive an alternative intervention.</P>
<P>If we encountered a multi-armed study, we planned to use data only from the metoclopramide arm versus placebo.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-10-29 07:50:02 -0400" MODIFIED_BY="[Empty name]">
<P>We attempted to contact investigators to retrieve missing data. We analysed all data by the intention-to-treat method.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>We assessed clinical heterogeneity by examining the trial conditions, that is, the characteristics of the studies, the similarity between the types of participants, and the interventions.</P>
<P>Statistical heterogeneity was assessed both by calculation of standard Chi<SUP>2</SUP> test and defined as significant when the P value was less than 0.1. When we found heterogeneity we explored the potential causes.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>We planned to carry out assessments of reporting bias when at least ten studies were included in a meta-analysis, following the recommendations on testing for funnel plot asymmetry as described in section 10.4.3.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We planned to explore possible sources of asymmetry with an additional sensitivity analysis, but in this review we did not have enough included studies to make such analyses feasible.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>All analyses were performed according to the intention-to-treat method.</P>
<P>We used Review Manager (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), which is the software package provided by Cochrane Collaboration. For dichotomous variables, risk ratio was calculated by random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). If the overall results had been statistically significant, we planned to calculate the relative risk reduction (RRR), the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>We explored statistical heterogeneity differences in reported effects, methodological heterogeneity, differences in study design and clinical heterogeneity differences between studies in participants characteristics, interventions or outcome measures (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We made a post hoc decision to conduct subgroup analyses on the basis of metoclopramide dosage.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-10-29 08:03:56 -0400" MODIFIED_BY="[Empty name]">
<P> There were too few included studies in this review to permit sensitivity analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<STUDY_DESCRIPTION MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>Nineteen potential studies were identified by electronic and manual searches up to October 2014. A further 58 potential studies were identified from electronic searches in 2014, but no new trials were identified for inclusion at this update (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>We found four RCTs enrolling a total of 204 participants (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>; <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>; <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>; <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>; <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Of the 204 participants, 108 were treated with metoclopramide, and 96 received placebo or no treatment. Participants designated to undergo treatment with metoclopramide were compared with those allocated to receive placebo or no treatment.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The studies included only adult participants. All four included studies were carried out in a secondary care environment, and all were conducted in the USA. Sample sizes varied from 105 in <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>, to 70 in <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>, 19 in <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>, and 10 in <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>.</P>
<P>The <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK> study included patients in the critical care unit who required enteral nutrition. In <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK> all the participants required feeding tube placement, but pregnant in-patients and intensive care patients were excluded. In <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK> all patients requiring additional nutrition were eligible for the trial, except for pregnant in-patients and patients currently receiving metoclopramide or neuroleptic patients. The <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK> study included patients that had previously had failed duodenal intubation. We also collected data on whether diabetic patients were included; <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK> included diabetic patients, but this information was not provided in <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>, <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK> or <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Metoclopramide was given intravenously in three studies (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>; <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>; <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>). In one study metoclopramide was given intramuscularly (<LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>). Two studies compared metoclopramide with placebo (<LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>; <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>), while in the other two studies the control group did not receive any intervention (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>; <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison</HEADING>
<P>Metoclopramide versus placebo (<LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>; <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>), or no intervention (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>; <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>All studies analysed whether metoclopramide improved the success rate of post-pyloric feeding tube placement. This was identified by ausculation and abdominal radiography in <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>, and by abdominal radiography alone in <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>, <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK> and <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>. Success rate of transport of pyloric tube placement was evaluated 45 minutes after placement in <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>; four hours after insertion of the feeding tube in <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK> and <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>; and with an additional abdominal radiograph 24 hours later in some patients who received metoclopramide after feeding tube insertion. In <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>, the success rate was evaluated by abdominal radiography one hour after insertion of the feeding tube.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-10-29 16:32:17 -0400" MODIFIED_BY="[Empty name]">
<P>Fifteen studies did not fit the inclusion criteria and were not included in this systematic review (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>The risk of bias of included studies is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>There were no descriptions of allocation concealment in the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Generation of allocation sequence</HEADING>
<P>Two studies used a random number table to generate the allocation sequence (<LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>; <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>). <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK> and <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK> did not describe the allocation method used, they simply indicated that the studies were randomised.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>Two studies were described as double-blind (<LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>; <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>), however full details of how this was achieved were not given in the published report of the <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK> study. It is therefore unclear whether participants, personnel and outcome assessors were adequately blinded. In <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>, the participants, nurses investigators and radiologists were blinded to the treatment protocol. In the remaining two studies there was no description of double-blind methods and we rated these as being at high risk of bias for this domain.</P>
<SUBSECTION>
<HEADING LEVEL="4">Placebo description</HEADING>
<P>Two studies reported a placebo of identical appearance (<LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>, <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>Three studies did not have withdrawals or dropouts. One study had withdrawal and reasons of withdrawal were described, but the analysis was not performed on an intention-to-treat basis (<LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>We rated all studies as being at low risk for selective reporting, as outcomes were reported, however we did not have access to the original trial protocols and we were therefore unable to assess whether there were any unpublished outcomes.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-11-20 12:51:23 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Sample size calculation</HEADING>
<P>Only one study reported sample size calculation (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Metoclopramide versus control (placebo or no intervention)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Failure rate of post-pyloric placement of enteral feeding tube</HEADING>
<P>In an analysis comparing metoclopramide 10 mg with control (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>; <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK>), failure of post-pyloric tube placement of the enteral feeding tube was observed in 41 out of 94 participants (43.7%) using metoclopramide compared with 43 out of 81 (53%) in the control groups. There was no statistically significant difference between the groups (RR 0.82, 95% CI 0.60 to 1.11; 175 participants; 2 studies; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). In this comparison there was no statistically significant heterogeneity (Chi<SUP>2</SUP> = 0.06, degrees of freedom (df) = 1, P value 0.81).</P>
<P>In an analysis of studies that used metoclopramide 20 mg versus control (<LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>; <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>), failure of post-pyloric tube placement was observed in 7 out of 14 participants in the metoclopramide group (50%) compared with 11 out of 15 in the control group (73%); this difference was not statistically significant (RR 0.62, 95% CI 0.15 to 2.62; 29 participants; 2 studies; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Heterogeneity was observed in this comparison (Chi<SUP>2</SUP> = 3.48, df = 1, P value 0.06).</P>
<P>When we pooled all four trials independent of dosage, the failure rate was 44% (48/108) in the metoclopramide group compared with 56% (54/96) in the control group (RR 0.82, 95% CI 0.61 to 1.10; 204 participants; 4 studies; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). In this comparison there was no statistically significant heterogeneity (Chi<SUP>2</SUP> = 3.24, df = 3, P value 0.36).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>As there were only four studies with a total of 204 participants, we did not perform sensitivity analysis or investigate publication bias using a funnel plot.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>
<LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK> reported that no adverse effects attributable to either metoclopramide or placebo were observed. <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK> did not report any adverse effects. <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK> reported that there were no 'side effects' of metoclopramide noted in any participants. <LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK> noted that adverse effects could include drowsiness, anxiety, agitation and urticaria, and rarely extrapyramidal effects, but did not report adverse effects directly attributable to metoclopramide administered in the course of that study.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-11-26 09:33:18 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK> showed that metoclopramide improves gastric emptying by increasing the amplitude of gastric contractions while relaxing the pyloric sphincter and the duodenal bulb and recorded a significant increase in post-pyloric intubation when metoclopramide was administered prior to the tube insertion. Although that study showed significant results, in our systematic review of four studies, we observed that metoclopramide was not effective in improving the success rate for post-pyloric migration of the enteral tube.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-11-26 09:33:18 -0500" MODIFIED_BY="[Empty name]">
<P>The four studies included in this systematic review demonstrate that metoclopramide, as administered, did not facilitate post-pyloric intubation in adults. However, the RCTs included had small sample sizes, therefore, we cannot rule out a beneficial effect of metoclopramide. Just one RCT reported that metoclopramide was effective (<LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>). Subgroup analysis in the <LINK REF="STD-Kittinger-1987" TYPE="STUDY">Kittinger 1987</LINK> study, demonstrated that metoclopramide was effective only for people with diabetes mellitus and with evident neuropathy. The other two studies did not find any beneficial effect of metoclopramide (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>; <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>).</P>
<P>Statistical heterogeneity was found in the comparison of metoclopramide at a dosage of 20 mg. This may be explained by clinical heterogeneity between the studies. The failure rates between the two studies were very different. In the <LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK> study there was a very similar rate between metoclopramide and placebo, whereas in the <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK> study, the failure rate was lower in the metoclopramide group, at 20%, compared with 100% of those receiving placebo. Other potential sources of heterogeneity were the poor methodological quality of the studies; use of placebo and double-blinding in one study (<LINK REF="STD-Seifert-1987" TYPE="STUDY">Seifert 1987</LINK>); and no intervention and no blinding for the control group in the other study (<LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>).</P>
<P>None of our included studies provided detailed information about adverse effects. Only one study (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>) noted the types of adverse effects that can occur due to metoclopramide but did not report adverse effects directly attributable to metoclopramide administered in the course of that study.</P>
<P>People who are given metoclopramide, especially at doses of 20 mg, may experience adverse reactions which may include depression, high blood pressure, decrease of libido, headache, skin rash, fatigue, fever, hyperactivity, insomnia, nausea, sedation, drowsiness, agitation, and extrapyramidal reactions (impaired speech or impaired swallowing, unsteady gait, inflexibility of upper and lower members, tremor). A recent publication also warns of the risk of developing tardive dyskinesia, or involuntary and repetitive movements of the body, with long-term or high-dose use of metoclopramide (<LINK REF="REF-EMA-2013" TYPE="REFERENCE">EMA 2013</LINK>; <LINK REF="REF-FDA-2009" TYPE="REFERENCE">FDA 2009</LINK>).<BR/>
</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>Potential sources of bias in studies analysing the effect of metoclopramide at the dosage 10 mg for post-pyloric migration of the enteral tube are the timing and methods to evaluate the outcomes; differences in the positioning of patients during the passage of the tube; and ability and experience of the nurse or physician, since training is a factor associated with the successful passage of the naso-enteral tube (<LINK REF="STD-Heiselman-1995" TYPE="STUDY">Heiselman 1995</LINK>). Since there were no differences between these studies in relation to timing, administration and dosage of metoclopramide, these explanations do not seem to justify the heterogeneity observed in these comparisons.</P>
<P>We should, therefore, emphasise that any conclusions we have drawn rely on only four primary studies that had a varying degree of bias due to limitations in trial design. The risk of bias should be considered when interpreting these results (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), and, given that the findings derive from studies with a high or unclear risk of bias, the findings reported in each study should be viewed with caution.</P>
<P>Overall, the quality of evidence in each comparison was rated as very low and the current body of evidence does not allow robust conclusions to be drawn concerning the efficacy of metoclopramide in assisting post pyloric placement of enteral feeding tubes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>We attempted to minimise publication bias by conducting exhaustive searches for trials, however only four studies fitted our inclusion criteria. These were published between 1984 and 1995, with none published since, so we were able to conduct only one meta-analysis. Sensitivity analysis was not possible for primary outcome measures for studies at low risk of bias, as there were too few such studies to permit us to assess the results of the review in this way.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-11-24 12:20:08 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK> reported that metoclopramide treatment before tube placement was superior to no drug in a small study, however, in the analysis that we carried out using data from four randomised controlled trials including <LINK REF="STD-Whatley-1984" TYPE="STUDY">Whatley 1984</LINK>, in this review, we concluded that metoclopramide was not effective in facilitating post-pyloric placement of naso-enteral feeding tubes.</P>
<P>A network meta-analysis of RCTs of methods to promote placement of post-pyloric feeding tubes, including prokinetic agents (metoclopramide and erythromycin) and gastric air insufflation, was published recently (<LINK REF="REF-Huang-2014" TYPE="REFERENCE">Huang 2014</LINK>). The findings of that analysis were broadly in agreement with our study, in that the authors concluded that none of the methods reached statistical significance and that the use of a prokinetic agent might induce more potential adverse reactions. The authors of <LINK REF="REF-Huang-2014" TYPE="REFERENCE">Huang 2014</LINK> recommended that clinicians in clinical practice should no longer use prokinetic agents for this purpose in either paediatric patients or in patients without impaired gastric motility. They also stated that gastric insufflation seems to be clinically better for promoting bedside placement of post-pyloric feeding tubes in adults but in their analysis the results for gastric insufflation did not reach statistical significance compared with other methods, and there are additional safety concerns with this method. It may in fact be that no technique is superior to the standard technique which is bedside placement performed blindly. The authors of <LINK REF="REF-Huang-2014" TYPE="REFERENCE">Huang 2014</LINK> concluded that more large, well-designed RCTs focusing on special populations were required to determine if there are methods that work better than endoscopic placement.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<IMPLICATIONS_PRACTICE MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<P>We identified no evidence to suggest that metoclopramide enhanced the post-pyloric placement of naso-enteral feeding tubes. None of the studies included in this review specifically addressed adverse effects, and information related to adverse effects can only be derived from reports of studies using metoclopramide for other conditions, which are outside the scope of this review. Adverse events related to long term or high dose use of metoclopramide may include irreversible neurological changes (<LINK REF="REF-EMA-2013" TYPE="REFERENCE">EMA 2013</LINK>; <LINK REF="REF-FDA-2009" TYPE="REFERENCE">FDA 2009</LINK>)</P>
<P>The Included studies were small and underpowered, used different doses of metoclopramide, and the overall quality of the evidence was very low, with a high risk of bias in several important features of the trials' designs.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>If future research is carried out, it should take the form of well designed and conducted randomised controlled trials (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>), with a participant population of significant size, administering metoclopramide versus placebo, control or an alternative intervention. Future research would help to evaluate the efficacy of intravenous metoclopramide to facilitate post-pyloric intubation of naso-enteral tubes and establish possible factors of migration (ability and experience of the nurse or physician, decubitus positioning during the passage of the tube, metoclopramide). Participant characteristics should be reported to minimise clinical heterogeneity within the sample. The intervention should compare standard doses of metoclopramide either intravenously or intramuscularly. Post-pyloric intubation should be evaluated by abdominal X-rays within four hours of metoclopramide administration.</P>
<P>The known safety profile of metoclopramide means that recording of adverse events should be a primary outcome of such studies. Given the safety profile and apparent lack of efficacy of this intervention, however, further studies are unlikely to be carried out.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-10-29 09:00:10 -0400" MODIFIED_BY="[Empty name]">
<P>We thank Jan Lilleyman, Karin Dearness and the Cochrane UGPD group for their support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-11-21 14:15:58 -0500" MODIFIED_BY="[Empty name]">
<P>Cathy Bennett is the proprietor of Systematic Research Ltd. and received a consultancy fee for her work on this review, she is also an editor of the Cochrane UGPD group. To prevent conflict of interest, the updated review was assessed independently by Prof Paul Moayyedi and Dr Grigoris Leontiades (CUGPD co-ordinating editors) prior to publication.<BR/>Cristiane Costa Reis da Silva: nothing to declare.<BR/>Humberto Saconato: nothing to declare.<BR/>Álvaro N Atallah: nothing to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>All authors, Cristiane Costa Reis da Silva, Humberto Saconato, Álvaro N Atallah, contributed equally to the production of the review including data extraction, data synthesis and writing the text. Cathy Bennett assisted with all aspects of review writing for the update produced in 2014.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]">
<P>In this updated review, we no longer use the Jadad scale to assess methodological quality (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Instead we independently assessed the risk of bias in the included studies using the risk of bias assessment tool described in Chapter 8 of the<I> Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>For the update in 2014 the authors CCRS and CB re-extracted data from all of the included studies and provided full assessments of the risk of bias. We compared the evaluations, and if there had been any inconsistencies we would have and discussed and resolved them.</P>
<P>We expanded the methods section to comply with current conduct and reporting standards for systematic reviews, including the 'Methodological Expectations of Cochrane Intervention Reviews' (MECIR). The methods were implied in previous published version of the review, but for clarity, the details are now stated explicitly. We describe how we planned to deal with assessment of risk of bias, measures of treatment effect, unit of analysis issues, dealing with missing data, assessment of heterogeneity, data synthesis, subgroup analysis and sensitivity analysis. In our review there were too few included studies to permit assessment of reporting bias, or any sensitivity analyses.</P>
<P>We present results as risk ratios (RR) in the updated version of the review (previously odds ratios (OR)).</P>
<P>We carried out Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessments of quality and present a 'Summary of findings' table that includes this assessment.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-11-24 12:25:44 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-11-21 06:37:02 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-11-21 06:34:19 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Heiselman-1995" MODIFIED="2014-10-29 08:28:28 -0400" MODIFIED_BY="[Empty name]" NAME="Heiselman 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-10-29 08:28:28 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heiselman DE, Hofer T, Vidovich RR</AU>
<TI>Enteral feeding tube placement success with intravenous metoclopramide administration in ICU patients</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>107</VL>
<PG>1686-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kittinger-1987" MODIFIED="2014-11-21 06:34:19 -0500" MODIFIED_BY="[Empty name]" NAME="Kittinger 1987" YEAR="">
<REFERENCE MODIFIED="2014-11-21 06:34:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kittinger JW, Sandler RS, Heizer WD</AU>
<TI>Efficacy of metoclopramide as an adjunct to duodenal placement of small-bore feeding tubes: a randomized, placebo-controlled, double-blind study</TI>
<SO>American Society for Parenteral and Enteral Nutrition</SO>
<YR>1987</YR>
<VL>11</VL>
<NO>1</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seifert-1987" MODIFIED="2014-11-11 04:27:55 -0500" MODIFIED_BY="[Empty name]" NAME="Seifert 1987" YEAR="">
<REFERENCE MODIFIED="2014-11-11 04:27:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seifert CF, Cuddy PG, Pemberton LB, Lyman EL, Schmitt P</AU>
<TI>A randomized trial of metoclopramide's effect on the transpyloric intubation of weighted feeding tubes</TI>
<SO>Nutritional Support Services</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>7</NO>
<PG>11-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whatley-1984" MODIFIED="2014-11-11 04:28:04 -0500" MODIFIED_BY="[Empty name]" NAME="Whatley 1984" YEAR="">
<REFERENCE MODIFIED="2014-11-11 04:28:04 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whatley K, Turner WW, Dey M, Leonard J, Guthrie M</AU>
<TI>When does metoclopramide facilitate transpyloric intubation?</TI>
<SO>American Society for Parenteral and Enteral Nutrition</SO>
<YR>1984</YR>
<VL>8</VL>
<NO>6</NO>
<PG>679-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-11-21 06:37:02 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Beau-1995" MODIFIED="2014-10-29 16:09:39 -0400" MODIFIED_BY="[Empty name]" NAME="Beau 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-10-29 16:09:39 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beau P</AU>
<TI>Pre and post operative enteral nutrition in elective surgery in adults. Methods, benefits and disadvantages</TI>
<TO>Nutrition entérale pré et postopératoire en chirurgie réglée de I adulte.Tecniques, avantages et inconvénients</TO>
<SO>Annales Francaises d Anesthesie et de Reanimation</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>Suppl 2</NO>
<PG>121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gottschlich-1996" MODIFIED="2009-05-13 09:18:33 -0400" MODIFIED_BY="[Empty name]" NAME="Gottschlich 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gottschlich M</AU>
<TI>How to smooth the way for cyclic tube feedings</TI>
<SO>Nursing</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>3</NO>
<PG>57-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalfarentzos-1987" MODIFIED="2014-10-29 16:10:15 -0400" MODIFIED_BY="[Empty name]" NAME="Kalfarentzos 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-10-29 16:10:15 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalfarentzos F, Alivizatos V, Panagopoulos K, Androulakis J</AU>
<TI>Nasoduodenal intubation with the use of metoclopramide</TI>
<SO>Nutritional Support Services</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>9</NO>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalliafas-1996" MODIFIED="2014-10-29 16:09:47 -0400" MODIFIED_BY="[Empty name]" NAME="Kalliafas 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-10-29 16:09:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalliafas S, Choban SP, Ziegler D, Drago S, Flancbaum L</AU>
<TI>Erythromycin facilitates postpyloric placement of nasoduodenal feeding tubes in intensive care unit patients: randomized, double-blinded, placebo-controlled trial</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>6</NO>
<PG>385-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keshavarzian-1993" MODIFIED="2014-10-29 18:25:56 -0400" MODIFIED_BY="[Empty name]" NAME="Keshavarzian 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-10-29 18:25:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keshavarzian A, Isaac RM</AU>
<TI>Erythromycin accelerates gastric emptying of indigestible solids and transpyloric migration of the tip of an enteral feeding tube in fasting and fed states</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>2</NO>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirby-1995" MODIFIED="2009-05-13 09:19:02 -0400" MODIFIED_BY="[Empty name]" NAME="Kirby 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirby FDC, Fleming RC</AU>
<TI>American gastroenterological association technical review on tube feeding for enteral nutrition</TI>
<SO>American Gastroenterological Association</SO>
<YR>1995</YR>
<VL>108</VL>
<NO>4</NO>
<PG>1282-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levenson-1986" MODIFIED="2009-05-13 09:19:13 -0400" MODIFIED_BY="[Empty name]" NAME="Levenson 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levenson R, Turner WW, Dyson A, Zike L, Reisch J</AU>
<TI>Do weighted nasoenteric feeding tubes facilitate duodenal intubations?</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>2</NO>
<PG>135-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1988" MODIFIED="2014-10-29 16:10:21 -0400" MODIFIED_BY="[Empty name]" NAME="Levy 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-10-29 16:10:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy H</AU>
<TI>Nasogastric and nasoenteric feeding tubes</TI>
<SO>Enteral Nutrition</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>3</NO>
<PG>529-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lord-1992" MODIFIED="2009-05-13 09:19:25 -0400" MODIFIED_BY="[Empty name]" NAME="Lord 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lord ML, Maimone WA, Pulhamus M, Sax CH</AU>
<TI>Comparison of weighted versus unweighted enteral feeding tubes for efficacy of transpyloric intubation</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>3</NO>
<PG>271-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marian-1993" MODIFIED="2014-10-29 16:10:07 -0400" MODIFIED_BY="[Empty name]" NAME="Marian 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-10-29 16:10:07 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marian M, Rappaport W, Cunningham D, Thompson C, Esser M, Williams F, et al</AU>
<TI>The failure of conventional methods to promote spontaneous transpyloric feeding tube passage and the safety of intragastric feeding in the critically ill ventilated patient</TI>
<SO>Surgery Gynecology Obstetrics</SO>
<YR>1993</YR>
<VL>176</VL>
<NO>5</NO>
<PG>475-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmieding-1997" MODIFIED="2014-10-29 16:10:29 -0400" MODIFIED_BY="[Empty name]" NAME="Schmieding 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-10-29 16:10:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmieding JN, Waldman CR</AU>
<TI>Nasogastric tube feeding and medication administration: a survey of nursing practices</TI>
<SO>Gastroenterology Nursing</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>4</NO>
<PG>118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulz-1993" MODIFIED="2011-02-18 11:18:27 -0500" MODIFIED_BY="Karin L Dearness" NAME="Schulz 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-18 11:18:27 -0500" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz AM, Santanello SA, Monk J, Falcone RE</AU>
<TI>An improved method for transpyloric placement of nasoenteric feeding tubes</TI>
<SO>International Surgery</SO>
<YR>1993</YR>
<VL>78</VL>
<NO>1</NO>
<PG>79-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stern-1994" MODIFIED="2014-11-21 06:37:02 -0500" MODIFIED_BY="[Empty name]" NAME="Stern 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-11-21 06:37:02 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stern AM, Wolf CD</AU>
<TI>Erythromycin as a prokinetic agent: a prospective, randomized, controlled study of efficacy in nasoenteric tube placement</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>11</NO>
<PG>2011-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thurlow-1985" MODIFIED="2014-10-29 16:10:42 -0400" MODIFIED_BY="[Empty name]" NAME="Thurlow 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-10-29 16:10:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thurlow MP</AU>
<TI>Techniques, materials, and devices</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1985</YR>
<VL>10</VL>
<NO>1</NO>
<PG>104-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ugo-1992" MODIFIED="2009-05-13 09:19:55 -0400" MODIFIED_BY="[Empty name]" NAME="Ugo 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ugo JP, Mohler AP, Wilson LG</AU>
<TI>Bedside postpyloric placement of weighted feeding tubes</TI>
<SO>Nutrition in Clinical Practice</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>284-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-11-24 12:25:44 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-11-24 12:25:44 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2014-10-29 16:12:13 -0400" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMA-2013" MODIFIED="2014-11-24 12:25:44 -0500" MODIFIED_BY="[Empty name]" NAME="EMA 2013" TYPE="UNPUBLISHED">
<AU>European Medicines Agency</AU>
<TI>European Medicines Agency recommends changes to the use of metoclopramide</TI>
<SO>http://www.ema.europa.eu/ema</SO>
<YR>(accessed 24 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2009" MODIFIED="2014-11-24 12:25:19 -0500" MODIFIED_BY="[Empty name]" NAME="FDA 2009" TYPE="UNPUBLISHED">
<AU>U.S. Food and Drug Administration</AU>
<TI>Metoclopramide-Containing Drugs</TI>
<SO>www.fda.gov</SO>
<YR>(accessed 24 October 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-11-21 06:37:31 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huang-2014" MODIFIED="2014-11-21 06:38:36 -0500" MODIFIED_BY="[Empty name]" NAME="Huang 2014" TYPE="JOURNAL_ARTICLE">
<AU>Huang T, Jong J, Yan M</AU>
<TI>How to promote bedside placement of the postpyloric feeding tube: a network meta-analysis of randomized controlled trials</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2014</YR>
<VL>epub ahead of print</VL>
<PG>Aug 21</PG>
<IDENTIFIERS MODIFIED="2014-10-29 17:13:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-29 17:13:26 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1177/0148607114546166"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2011-02-18 11:20:08 -0500" MODIFIED_BY="Karin L Dearness" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2014-10-29 16:10:56 -0400" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz K, Altman D</AU>
<TI>The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rang-1997" MODIFIED="2014-10-29 18:21:25 -0400" MODIFIED_BY="[Empty name]" NAME="Rang 1997" TYPE="BOOK_SECTION">
<AU>Rang HP, Ritter JM, Dale MM</AU>
<TI>Gastrointestinal tract</TI>
<TO>Trato Gastrintestinal</TO>
<SO>Farmacologia</SO>
<YR>1997</YR>
<PG>306-20</PG>
<EN>3rd</EN>
<ED>Rang HP,Ritter JM, Dale MM</ED>
<PB>Guanabara</PB>
<CY>Rio de Janeiro</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-11-21 06:39:12 -0500" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sumner-1986" MODIFIED="2014-10-29 18:21:53 -0400" MODIFIED_BY="[Empty name]" NAME="Sumner 1986" TYPE="BOOK_SECTION">
<AU>Sumner M</AU>
<TI>Drugs acting on the gastrointestinal tract</TI>
<TO>Drogas que atuam no trato gastrintestinal</TO>
<SO>Farmacologia Moderna</SO>
<YR>1986</YR>
<PG>860-73</PG>
<EN>1st</EN>
<ED>Craig CR, Stitzel RE</ED>
<PB>Roca</PB>
<CY>São Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Troncon-2000" MODIFIED="2014-10-29 18:20:24 -0400" MODIFIED_BY="[Empty name]" NAME="Troncon 2000" TYPE="BOOK_SECTION">
<AU>Troncon LEA, Marchini JS, Inamuno MRDLD, Moraes AC</AU>
<TI>Intestinal tubes</TI>
<TO>Tubagens Intestinais</TO>
<SO>Tubos, Sondas e Drenos</SO>
<YR>2000</YR>
<PG>144-55</PG>
<ED>Pohl FF, Petroianu A</ED>
<PB>Guanabara</PB>
<CY>Rio de Janeiro</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-11-21 14:21:56 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Silva-2002" MODIFIED="2014-11-21 14:19:48 -0500" MODIFIED_BY="[Empty name]" NAME="Silva 2002" TYPE="COCHRANE_REVIEW">
<AU>Silva CD, Saconato H, Atallah ÁN</AU>
<TI>Metoclopramide for migration of naso-enteral tube</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-11-21 14:19:48 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-21 14:19:48 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003353"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Silva-2009" MODIFIED="2014-11-21 14:21:56 -0500" MODIFIED_BY="[Empty name]" NAME="Silva 2009" TYPE="COCHRANE_REVIEW">
<AU>Silva Cda, Saconato H, Atallah ÁN</AU>
<TI>Metoclopramide for migration of naso-enteral tube</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-11-21 14:21:56 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-21 14:21:56 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003353"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-11-26 09:19:34 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-11-26 09:19:34 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Heiselman-1995">
<CHAR_METHODS MODIFIED="2014-10-29 08:44:01 -0400" MODIFIED_BY="[Empty name]">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-21 05:54:40 -0500" MODIFIED_BY="[Empty name]">
<P>Number of participants randomised: 105; 46 in the control group and 59 in the metoclopramide group</P>
<P>Inclusion criteria: admission to the critical care unit; need for enteral nutrition</P>
<P>Did not state whether diabetic patients were included or not</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-24 08:07:25 -0500" MODIFIED_BY="Cathy Bennett">
<UL>
<LI>59 participants received metoclopramide 10 mg intravenously 10 minutes prior to the insertion of the naso-enteral tube</LI>
<LI>46 control participants received no medication prior to the insertion of the naso-enteral tube</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-21 05:57:16 -0500" MODIFIED_BY="[Empty name]">
<P>Success rate of post-pyloric tube placement evaluated by auscultation of the right upper abdominal quadrant and abdominal radiography taken 45 minutes after tube advancement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Setting: Ohio, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-21 05:59:31 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kittinger-1987">
<CHAR_METHODS MODIFIED="2014-10-29 08:46:38 -0400" MODIFIED_BY="[Empty name]">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-21 05:58:38 -0500" MODIFIED_BY="[Empty name]">
<P>Number of participants randomised: 70</P>
<P>Inclusion criteria: all patients requiring feeding tube placement were considered eligible, including diabetic patients</P>
<P>Exclusion criteria: pregnant in-patients and intensive care patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-21 05:59:29 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>35 participants received metoclopramide 10 mg in 2 ml volume intramuscularly</LI>
<LI>35 participants received 2 ml of diluent as placebo.</LI>
</UL>
<P>Either metoclopramide or placebo was administered immediately after insertion of the feeding tube</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-21 05:59:29 -0500" MODIFIED_BY="[Empty name]">
<P>Success rate of post-pyloric tube placement evaluated by abdominal radiography 1 hour after insertion of the feeding tube</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-21 05:59:31 -0500" MODIFIED_BY="[Empty name]">
<P>Setting: North Carolina,USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-21 12:16:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seifert-1987">
<CHAR_METHODS MODIFIED="2014-10-29 08:48:15 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-21 06:00:43 -0500" MODIFIED_BY="[Empty name]">
<P>Number of participants randomised: 19</P>
<P>Inclusion criteria: all patients requiring naso-enteral nutrition were considered eligible</P>
<P>Exclusion criteria: pregnant in-patients or patients currently receiving metoclopramide or neuroleptic agents</P>
<P>It was not stated whether diabetic patients were included or not</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-21 06:01:33 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>7 participants received metoclopramide 20 mg in 4 ml volume intravenously</LI>
<LI>9 participants received 4 ml of normal saline as placebo</LI>
</UL>
<P>Either metoclopramide or placebo were administered 15 minutes prior to the insertion of the naso-enteral tube</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-21 06:01:38 -0500" MODIFIED_BY="[Empty name]">
<P>Success rate of post-pyloric tube placement evaluated by abdominal radiography 4 hours after insertion of the feeding tube</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-21 06:01:40 -0500" MODIFIED_BY="[Empty name]">
<P>Setting: USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-21 06:06:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whatley-1984">
<CHAR_METHODS MODIFIED="2014-10-29 08:50:40 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-21 06:05:18 -0500" MODIFIED_BY="[Empty name]">
<P>Number of participants randomised: </P>
<UL>
<LI>12 were included in the non-randomised pilot study</LI>
<LI>a second group of 10 patients (5 in each group) were randomised to receive metoclopramide or placebo</LI>
</UL>
<P>Inclusion criteria: all 22 patients that had failed to achieve spontaneous duodenal intubation were considered eligible</P>
<P>Exclusion criteria: no clearly described</P>
<P>It was not stated whether diabetic patients were included or not</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-21 06:06:02 -0500" MODIFIED_BY="[Empty name]">
<P>In the randomised comparison:</P>
<UL>
<LI>5 participants received 20 mg of metoclopramide intravenously 10 minutes prior to the reinsertion of weighted tubes</LI>
<LI>5 control participants did not receive any intervention</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-21 06:06:26 -0500" MODIFIED_BY="[Empty name]">
<P>Success rate of post-pyloric tube placement evaluated by abdominal radiography 4 hours after insertion of the feeding tube. In participants who received metoclopramide after feeding tube insertion, an additional abdominal radiography was also obtained 24 hours later</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-21 06:06:28 -0500" MODIFIED_BY="[Empty name]">
<P>Setting: USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviation</B>
</P>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-11-24 12:21:50 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:07:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beau-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:07:14 -0500" MODIFIED_BY="[Empty name]">
<P>Examined the techniques for enteral nutrition, was not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:07:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gottschlich-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:07:29 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:07:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalfarentzos-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:07:34 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:08:25 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalliafas-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:08:25 -0500" MODIFIED_BY="[Empty name]">
<P>Determined whether administration of erythromycin could facilitate passage of a nasoenteric feeding tube to the duodenum for post-pyloric feeding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:08:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keshavarzian-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:08:34 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT, was a crossover study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:07:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirby-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:07:43 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:08:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levenson-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:08:40 -0500" MODIFIED_BY="[Empty name]">
<P>Compared the frequency of duodenal intubations using weighted and un-weighted nasoenteric feeding tubes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:07:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levy-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:07:46 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-24 12:21:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lord-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-24 12:21:50 -0500" MODIFIED_BY="[Empty name]">
<P>Compared passage of weighted versus un-weighted enteral feeding tubes.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:09:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marian-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:09:45 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT, was a prospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:07:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmieding-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:07:55 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:09:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulz-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:09:51 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT, was a prospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:09:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stern-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:09:57 -0500" MODIFIED_BY="[Empty name]">
<P>Determined whether erythromycin ethylsuccinate elixir would facilitate the post-pyloric passage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:08:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thurlow-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:08:02 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-21 06:08:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ugo-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-21 06:08:05 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviation</B>
</P>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-11-26 09:19:34 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-11-21 06:06:31 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:57:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heiselman-1995">
<DESCRIPTION>
<P>No details about randomisation provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:59:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kittinger-1987">
<DESCRIPTION>
<P>Generation of the allocation sequence: random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:01:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seifert-1987">
<DESCRIPTION>
<P>Generation of the allocation sequence: not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:06:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whatley-1984">
<DESCRIPTION>
<P>Generation of the allocation sequence: random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-11-21 06:06:32 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:57:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heiselman-1995">
<DESCRIPTION>
<P>Concealment of allocation sequence not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:59:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kittinger-1987">
<DESCRIPTION>
<P>Concealment of allocation sequence not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:01:43 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seifert-1987">
<DESCRIPTION>
<P>Concealment of allocation sequence not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:06:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Whatley-1984">
<DESCRIPTION>
<P>Concealment of allocation sequence not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-11-21 06:06:34 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-21 05:57:24 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heiselman-1995">
<DESCRIPTION>
<P>No blinding of participants, personnel or outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-21 05:59:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kittinger-1987">
<DESCRIPTION>
<P>Double-blind method: not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-21 06:01:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seifert-1987">
<DESCRIPTION>
<P>Double-blind method: the patients, registered nurses, investigators and radiologists were blinded to the treatment protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-21 06:06:34 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Whatley-1984">
<DESCRIPTION>
<P>No blinding of participants, personnel or outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-11-26 09:19:34 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-21 05:57:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heiselman-1995">
<DESCRIPTION>
<P>There were no withdrawals or dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-21 05:59:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kittinger-1987">
<DESCRIPTION>
<P>There are no withdrawals or dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-26 09:19:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seifert-1987">
<DESCRIPTION>
<P>Reasons were provided for withdrawals and dropouts. 1 participant was lost due to the accidental removal of the tube before the medication was taken and 1 was lost from each group before the X-ray to determine to determine correct placement had taken place.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-21 06:06:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whatley-1984">
<DESCRIPTION>
<P>There were no withdrawals or dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-11-21 06:06:39 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:57:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heiselman-1995">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:59:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kittinger-1987">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:03:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seifert-1987">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:06:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whatley-1984">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-11-21 06:06:40 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:57:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heiselman-1995">
<DESCRIPTION>
<P>Sample size calculation was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 05:59:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kittinger-1987">
<DESCRIPTION>
<P>Sample size calculation was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:03:25 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seifert-1987">
<DESCRIPTION>
<P>Intention-to-treat analysis: no</P>
<P>Sample size calculation was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-21 06:06:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Whatley-1984">
<DESCRIPTION>
<P>Sample size calculation was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-11-21 06:12:07 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-11-21 06:12:07 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-11-21 06:10:35 -0500" MODIFIED_BY="[Empty name]">Metoclopramide for post-pyloric placement of enteral feeding tubes</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Metoclopramide for post-pyloric placement of enteral feeding tubes</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients needing post-pyloric placement of naso-enteral feeding tubes<BR/>
<B>Settings: </B>hospital<BR/>
<B>Intervention:</B> metoclopramide <BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Metoclopramide </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Failure rate of post-pyloric placement of the enteral feeding tube assessed by abdominal radiograph</B>
<BR/>Radiographic assessment of successful tube placement<BR/>Follow-up: mean 4 hours</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.61 to 1.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>204<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>562 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>461 per 1000</B>
<BR/>(343 to 619)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>572 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>469 per 1000</B>
<BR/>(349 to 629)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Design limitation (risk of bias)<BR/>
<SUP>2</SUP> Statistical heterogeneity present in the analyses of trials comparing 20 mg metoclopramide versus control<BR/>
<SUP>3</SUP> Small number of trials with relatively few participants/events<BR/>
<SUP>4</SUP> Insufficient number of studies to assess publication bias using funnel plots</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-11-21 14:10:11 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Metoclopramide versus placebo or no intervention for post-pyloric placement of enteral feeding tubes</NAME>
<DICH_OUTCOME CHI2="3.23721030654363" CI_END="1.1038144614407837" CI_START="0.6127545058543166" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.822415518381673" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="54" I2="7.3276149548930505" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.042896079603126705" LOG_CI_START="-0.21271348650514424" LOG_EFFECT_SIZE="-0.08490870345100876" METHOD="MH" MODIFIED="2014-11-21 06:40:35 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3564778975199059" P_Q="0.7162219652283854" P_Z="0.19287312981012794" Q="0.13214153276488194" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.007506787020587765" TOTALS="YES" TOTAL_1="108" TOTAL_2="96" WEIGHT="100.0" Z="1.302126546136209">
<NAME>Failure rate of transpyloric placement of the enteral feeding tube assessed by abdominal radiograph</NAME>
<GROUP_LABEL_1>Metoclopramide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metoclopramide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05842173346464298" CI_END="1.1143913151584992" CI_START="0.6014261009604307" DF="1" EFFECT_SIZE="0.8186721099560816" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="43" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.04703771882021669" LOG_CI_START="-0.22081772811925213" LOG_EFFECT_SIZE="-0.08689000464951774" NO="1" P_CHI2="0.8090080737169566" P_Z="0.20351852297486073" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="81" WEIGHT="78.30898067578829" Z="1.2715909396313902">
<NAME>Metoclopramide 10 mg</NAME>
<DICH_DATA CI_END="1.2360014892147762" CI_START="0.5736409640940598" EFFECT_SIZE="0.8420338983050848" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.09201899401927763" LOG_CI_START="-0.24135984296651838" LOG_EFFECT_SIZE="-0.07467042447362039" ORDER="1875" O_E="0.0" SE="0.1958283790973146" STUDY_ID="STD-Heiselman-1995" TOTAL_1="59" TOTAL_2="46" VAR="0.03834875405988156" WEIGHT="49.16291075314503"/>
<DICH_DATA CI_END="1.305589982246061" CI_START="0.46334475588135077" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.11580680909364933" LOG_CI_START="-0.33409574794378544" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="1876" O_E="0.0" SE="0.26427498905736396" STUDY_ID="STD-Kittinger-1987" TOTAL_1="35" TOTAL_2="35" VAR="0.06984126984126984" WEIGHT="29.146069922643267"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4779731633694064" CI_END="2.6208553169355726" CI_START="0.148310730743961" DF="1" EFFECT_SIZE="0.6234588737269766" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="71.24762173175553" ID="CMP-001.01.02" LOG_CI_END="0.41844304658915543" LOG_CI_START="-0.8288274252744421" LOG_EFFECT_SIZE="-0.20519218934264336" NO="2" P_CHI2="0.06219098746376561" P_Z="0.5190055703978111" STUDIES="2" TAU2="0.7896975081242907" TOTAL_1="14" TOTAL_2="15" WEIGHT="21.6910193242117" Z="0.644879054050894">
<NAME>Metoclopramide 20 mg</NAME>
<DICH_DATA CI_END="2.2046520706307184" CI_START="0.5599831001366924" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3433400605939513" LOG_CI_START="-0.2518250794726011" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="1877" O_E="0.0" SE="0.3496029493900505" STUDY_ID="STD-Seifert-1987" TOTAL_1="9" TOTAL_2="10" VAR="0.1222222222222222" WEIGHT="17.37770053771713"/>
<DICH_DATA CI_END="1.1134492935069173" CI_START="0.06680157392258843" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.04667044404489699" LOG_CI_START="-1.1752133049220221" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="1878" O_E="0.0" SE="0.7177405625652734" STUDY_ID="STD-Whatley-1984" TOTAL_1="5" TOTAL_2="5" VAR="0.5151515151515151" WEIGHT="4.313318786494574"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-11-26 09:19:35 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-11-21 14:10:12 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUIAAALyCAYAAACvj910AABHv0lEQVR42u2dD6RUTcD/H5IkSSRJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-11-26 09:19:35 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAXH0lEQVR42u1dW2wc13n+Ke7cuLzNLBmbdiBIIuEXxUAqQ5aomI6x
klMTdqs0aFADbRFLDzSEyC6KvNgFekkfKsGAH5w4QSUUVdtcUKOGCim1pVryGtZSLUy1AorYaWGQ
oirXXDokZ0iJ5O7MLLk9l9m57YXL5ZBcUv/Hy8ycOef8Z89+c84/s+fbHwCBqI4mULETENVg7MA+
QKwA5AgCOYJAjiCQIwjkCAI5gkCOILY7YtgFZWBgF/ierSJHGnN43fQG5HGuQaA/gkCOIJAjCOQI
AjkSGfQNL4ioxpEkgaiMlMuX3KwGPlzBthZfoYUPlS+YLJ+7NYtcqG0cSaVSk+LXG6qB/aRV5UaJ
3/1shYKHyhcsvtLQ8R0Vx52a5xptfAmgSxFllVxsnbKYBrDjIn3oZrdILaQjk2fEw1pakviFp0mi
TPb0FimusyznkvwiJX92qxi3yV7HoEiy2IPiOTeNVTekkkwjcbFlhJvS3HqSnRJpg0DakGQ/MOLY
7iza3dOuUduKZxvcurqpPacgabuvDRTdCrNHXuSLkkReV1YUBtOgndyDZKjZH+kjSQu61bJI9gsT
7x8GSIiT9D1QJVPeSbZDk/9iPpeZ7WC5F1qsFvLe7pwzL5P+TsiZl7yaEoYlJejOz95vJ8W/13GC
pYkJflY4TWvd/5k1c4RslydaF9x64O0MaYNN2pDiV3zSsb1ctJs/ymwrnm1a1wfWzH7yrv/7Qmex
YEKwLsTcNlCYn7fsZzvzf2DOEpMd79rnnwY4aiMZauII9UfMa6SXFdC/Ro7HtYEnSK+OaTfo2zIG
o/QJ7Q1NOTCuKU+wEjFbGyUXaF6AAYXkHNV8H3WYAugmr2UAwNo3lWNphsnPjrO8sgaKRba3NWrR
qQf2aW4bOCWIbZvlcuxae8O2aV2Pg0L27FuC6bbhFuyT3TZQzGjTMtvJDQCtLHY4myUN24scqYTA
uvhkCtJv/SUd8ncv5Q+l6DH9k0y2oUeiVUxkfyTnl/Mv/PMUm12GLXq6mJNuSKJ42T1KFX3FYcoJ
Ny/ZTdv+IsPchteGUtsAz1ymtpe+49kO1gW+gqT9XkH6f+gs3djd33+lP0VrKXRM8fYUYeDnNXm1
YmcMPLaT3UyI1wK3kXRWuE42AyXuy+LkP90l54i3S/q4SYcR785zmCRednMOM59hmGcEN28TSfAu
4evu6WAbSmynRqjtjM+2V9ewz/0k+3oh0OJu0P+B7bQX2u+yV5A5Q7YjOF7UzNdjQMaR5f8ZPeIl
SXvYYCMo0PdROLuS1ZroORvOkVFe6gVabjit76JDvw1XW9yc4k1bZmkqT5N2w5FhgKsjoCluJqce
CtKG/S61XgvbFh8ltrWi7SyfPZy6xD22RKjDmGf2wU0z0OIsPMK916Xpo9QzIrU8T1j0qIhkqHlM
Uw7o0HK8x3dixmauZyohZkvuJt/ThIVZcq5DPHGX5hRpublkTzMt1ym87j3FUF5vNVjaQZ42k5do
XuMpKXvXGx54PRTx4z2UmeKD7A44IeYCtoUHiO2ssEDqSnWK6j0+KvK6jFzrVeJntLIh0xSO5oOv
bzDLfaYzbT2UYu8dEDtI1gdwlURN/kgkSKZqznrtmcW6n6L2ZLRIH+cG6kN/xO+PRM8Rv+9XDYUj
aWFWqNvMuZfmo2x1/M1jgBzZKI5sB+BaRd9aRQNn4ar9gwBcG4BAjiCQIwjkCGLzgT4r3tes5Lcj
R/DSKQvUYCHQH0EgRxDIEQRyBIEcWUchgr75TbjP0AxKXTfPh2ZzAMlx+lsOb+QrnakJ1cr+gN+V
qTGrepkflG+CkxY+VdByvqMcDq/Lylo7w/7oD6uery6AWhP6+Shx0Fg53yo0WPmDOO5EO9fo1md/
7fapHRdbbbKRJQ2gSxaHXOWU3SpwAZQspHlWlkdvERXdlV05aXGRiqwyiihf5Re6KkpaF5NcOed4
/iSXYfZeFyArinKXK7NiLWH2bEVymxC0xdvA2uTaSgu0FuF6L5IhUo70mZrg9mlCtGIJgE6lbRFg
/orV7yqnEjFbpE8sCxOpwywrz6NKlsIEVUx25aTNWv+qAhzXLeVZh4eTszmLSa7ouV3F/E7VlgjQ
0Wq1zhMrs5b0Km/JLFt5q0ptB4v5grZYysRlLgKjtp4jbGmzrtwDEE0kQ6QcsTS44AoezDG4ZVKZ
1HSOCZuOucqp52/B2ItAlVMDXDnF88iuoIrJrliawoVUlxQwnOKGphzkkit6zpNpOXPDpwDCn6c/
5bIu/YfcHtl7nmqwpi8V8wVtUdzRBp5nO9TWIbq2Mr2XNP/TJSRDBdS1VlF/kLxzw5NaiT6KvD/d
+QEzVU0ABSFBlafNStug73rhrCu88guzfDItll+gc0qnPfBf0yEN1nWzRIMVEG95bXJskVqa2qZD
Giz8vKaKBqu2qUZIpVJin3M07Eq0CDoKl/7WzXddD92B8jw0uSmcxuVTD+/46b0Sc9cDMi1n/COl
hIXJV+f9si6a0SzW6DWhKehuF9vk2CK1KKSWUC7EGueaGapXEo47Ry/3wR4ZINbXTf7np/e+7r7x
uT7o9d9SOnmomEsIpeW4+GpZGC29hHOeMIuOKExRF/uEzCNZTVr2S72kDBN4xXq7Bov5grYo2uET
id/dcVtyWsuQeeYTHDoi5ciLY+Tf2JvO9XjKFOwZgNnFe+T9mWvr+RuS9loPG69M0QoMJDzPnYSY
uxNKMzokKr6Kz79SKpsxPGEWJQJzbcSPAdpU8fD7TNb1W1zWNd4n5kjTZr9973wx352E5LNFcffk
MzNsx7HV+pZINZ0fo04vUn+kAaD//kUhyvrs3/6Zhv5IeX9ky+pr1GgdiELCP+AhR/wc2bKdYUTr
YzYFnes8zjA+LxK7oNwghV2w5mdoCOQIAoEcQSBHEOizrvNNE3YBarDWfXhdawWb/il0AecaBPoj
COQIAjmCQI4gkCMbD32FY0QUHKFRJ+RutrY0GCYqWSEW1bnWMolZsVBPQyrEp6qaObD3cCjPw6uK
gxU/h1yoaRxJpSYVvpy0RL1UNhbViXKpHa1r+dS+fuVWf+nxKjRYn53AcafGuUYzlt2RQ+WRqaig
iSdwKZUdlzr5VdgrPg7JLBNAFaNZqXLyia/SyFRO1CoqpZKdqFndikjVVk69XHrllKPobmFl3HxO
lCuCNIuI5dl31VR8j9dBFVdORCxSwTkvDlZIBlbBjiZiHKxa/RFfDAguW3pLyRSf+RUm7tKoWELm
FD+2viD/zk7SuFb7Z3k0K5ig2qedkin/hBxczAD81aSRMzOznQC/F7fiC269P1ZuL/rKAfz6/1p2
sh0n33yLpfPnwd9gEbGK9mPiJF+PColLk3QtEK+D2n1rzpym0c9+0XHClYFdsHncLVa2ip0vMMZR
TRwhDslXX3OPxpls6e1RzXlLnCBU5i3tMec6/iUd0rUxKqsSQKFCtzF2iR8Yg9GLZPsVcvSYphzc
pymkpjeni8G16ObiWI+vHEFemz7Adpx8gs3iU4EXlYvbl3lULgLzK9pt8Nfxx2TvSDHiFkduH9D2
gRu4q5KdXyJHKsG/npXKk7rvmj71EvnzQlsFo2IBuHtU0gRhmVQoYhaLO2Uv96fKSq/AL8xy8o08
tQTzbF2zvntWOVTZvmfbF0WrahyssnYkn5jTwM9rCpU1WFPhm5IdYR0VuAkF3T0KyqRKhU/MmS1M
++6DAtIriq5iGSff44uZlu/yO5SmxLVy9oFH0vLqcCJiDYc0WMGXVMGOXsABo0a+q83hW9le2BVI
oFGxhtmeQJV6u6BXYjIpnyfzWonwiQ3y01nfpRrrzQwGymXhkZw/H42w9XfcMfrvQFSum8UGkT2a
7tRB2PAa3xNvUlWXIwP7GHrl4Asqb0dBfU2N/oiY+zCU4YYlnQ8kzNjiWb7HlHrNojXDJFRZb5Ao
iVrFMNf2bZ+1D7K7PgqUaxlcvOHPF/+WsDDHn10cf9Afleuo9Iaz902JMprUsXiXkO5B6O8UFz+k
EbfuGuyYEmGQtc+HCnb+FFdJ1OKP1AzVYt/ToD80oSVT26Mf7LaJSONgbSd/ZPUcabULsfgUv1E2
F2qNetXoaJ3yf+cXcmRtHLkfgGsVMQ5Wzf2DAFwbgECOIJAjCOQIYvOBPive16zktyNHcHgti2Xs
DAReMAjkCAI5gkCOIJAjIeh1nVptEd1/CrUQUaGez31rXjPiZXRUEOXAlryvrjY58AXjqj3vpTuG
SF5Sb7mGOmnhU61i4PtZcXhdVje6M/ornzq4+toOBQYPLyLWIddQitW7Cg2WkcVxJ+K5Jtk5JJIr
1j4pXQNXcqUOSVqapSezksL7XH9DjOtcIBVnucDLT+thPxmFarRm4kNMLnVVGsqm5SGWIsb5QkM7
PkR53aVITpSt7pNMQAU8IpabzurrHHLq5XGwuByMtYtVJdM6k7SyISovy4riyTQIixgHK2p/ZPn0
HI1Q9dO2UwA7ZVOisib99GzuWZYOcubHfKxS+61plQmi1FnzR7tYWjG/c0Gn4JTU3gmgCWdZ1Kxv
Zfq15yb6STWnZi2J671i4mm6Mmv+PbOfh8K6949WnE8x1ju+dKa8ajrt1Ett/chitnh7WVUTl3ez
nf362TiZ5zri1mNPA3RbSIaIOcL1UDzilD0KY1S84EWugrx2lK/9kx8Hhe8pAhzj70Mxv4szt6ZM
gBdvwRiNGjKjHesf146Ran7oRrh6cYzJrWiULS6lyk2D7sTW2utPpxjzrUy1j3Jbt10N1g1tgC/P
v8SlXeJfpI8S/+ZT/PrviH3WoJCqRHJFN0JIFlVObuUTSkFYLuUVBlduZXfn81yNZXfbT5peRCw3
PdC2SnGweMLI00t5Jw7W7R5eD/qs0fus5eJaOTeeOq/5eiBIlQ3B/I6fOOxW851ALX1uYUd41V6Y
cuLydhSmLzojoe5PL9PCUNu6QX+B7Xy96V0nDtY7ZPLRkRbr83yER5wSLkBvSHK1C/p4sKncCJNF
Ddu+aFZO/mFN38UJIvZ2Szxq1plALe02qINsT9rDhFdL01kWZcuG/JVswmmD4k8fHikW5sQrbdsC
KO1sZ0mQaRVONK0L+An4+nBkNksjTt35rmgGY03Becm8zQeqp0QqkBJai5GuwM3futBD3xfxATBy
v3OVRc2yg07BqU4h9x9sbyYv0bzv8yhbpLa5J3scaRhVhHnpouuWkHq5rVAcrDm560/YTnx+gEq4
nGhaL6BOL0p/JMKnbBEgmohYUWuwtpM/sj4ckTYyoLI2E0G4o4LmX3uGHPFzZH1m4Q2NuR1J0LSm
4PLEZZxhfF4ndkEZoAYrOp8VgRxBIJAjCOQIAn3W9QFqsFCDdR8Mr2t9BXmcaxDojyCQIwjkCAI5
gkCOVIK+ASXWVg4RRuRrA+yOpYI8467oCK8kUbKrXVwi58qXUFf4vLdCuUoarIi/n3Xr3/uuowar
XcpMQqLi6f5Vh7o6VCEIVy5fVzkH4VN3VBx3NmyuWR7TtLs5f4QrJzqVPehGpxq0yVExnV7UnbIb
Seuc2EIXuruRtBwtFcnCo3LJThCuC4JQVzmwFZYfoEuWuAZLGEyDdhLjYG0YR4Tdqg0WwP4PrJn9
LGXnnHmZvBex77nRqa5/Cb70b8V0isyEm/+lyYtkFFIlU6bSqbczjpbKiZ6lShPO8p+TYn3lIPF5
C2/X/BVzlpzqfNc+/zTAUdTXbBhH7ixZcaXLL77KCzBA9iQvOtU7FthCMZ0iq7n5DW2fScqMwSgV
WuxzF5neZtGzlFvFqFz2p/WVgxltmgcryQ0A1WU1H2ZxsPaiTm/DfFY6uey2slWjU+k9JvUooaiw
YgopNz88c7m8TMuLygVcMlVPOU8eZnd//5X+FOhffjLVMRV1HCz0WatA0kGbWyLkqxKdShM6Y355
FiOrk38E9A+4dGqgHKV1cOR0O/T6ylENFo/j1L7cTrUc2uLPz5DtCMbB2rC5JrfH1juIr3DVjXAl
cPGVPzqVuG/KTXdQzH8EbkrknAJ9H/ETw35pcK4XEjwGa+yT+srBIjzCpTRLM0fp/Zeiac8TfjyK
+poN44hhtD6YN3iEKy65SnWIJ3h0qivkTWTRqb64nnXTi+Wc/M3CN2+Tcwkx69yeCv5g5DdM6Txv
sjhYXzloGczeZjvvt/XQpPcOiB0k6wO4SmIj/ZG1YOUHbFqOffGR/tDniXrKVfKhXjm9vTRYEfoj
jcaRFeJqFaSm5jn+EFez5usqVx7xN48BcmRrcKQxgGsVMQ5Wzf2DAFwbgECOIJAjCOQIYvOBPive
16zktyNH1md43fLjM2qwEOiPIJAjCOQIAjmCQI40BlAOgRypBE0RWTysP+PLXUuQDGwQ9yFHun7j
PUt/rhvgV9XzpfDtv285krs5AMp//pqLsFRZSNM4WiKLsdXBF9DaMjsCyCiifBUgLYhyF5LhPuKI
PUb+3ZK44GtpInUYIDFrSa+S1ObPWQ514jJf6Hhct5RnCVvarCv3kAwVsB3XofG1rTxcUvJtjW6o
eIYmvM0WrdLN0FmfPDzedGmvbzlrBGsVt/6z+A2Py7mhYDFsinoZ/tZ/LZlMFtwjuvl7fufT/jIV
7c0WDvfgXHM/zTXib5J/3wjENRgO6L3ALt4WP7zjp04sLGUeyXAfcUTOZiGdG/bLsF62QY17Odrh
Ex6ma1kYpZ98y2ntF0tIhgpoBmXbvabFe9qOn+s/IW99bGn3OAD5+7Dz2M34It2j2P2rPxq90kyP
5punxnvGobNJ+99rPmlFbs3hTpq2eicuK77OwDXgpUCfdbv7rIhogevQyo+0m14BcqTBgfPvdr+v
QSBHEMgRBHIEgRxBIEcQyBEEAjmCQI6sFcYml2+sCpAjCBxHEMgRxHoD14+sy2y+DYDfvVlrB9XJ
sbVeeA1QAc41CPRHEMgRBPqsiMZx4NFnreiyqWyj1u7/uWXYdlVFPT9Rrc+252eqNbeAn/JaXcko
cqRi95E/9lszRYq9qzpHtRcN3E7VY9srbkCtLTBCr7SiUfRHor5frv+u01AjI3ek1nAcifydM+qm
ixF+MLN622rNLVBrfsHIkapDg0F/jZr9+uJUQ7arLQpuyTptl9RTVwvKlUGOrDzDq6u6ntW6i6pr
tr3WFpQvg/5IhFONscaZYu3TnLp2D6e0DHIkajrV/3lgVJ8kRv2JJD5Dq+4+GsXnDKt6OrHaoiUP
WOqtQF1N48s9HylTBuNyIlYkHs41iJWAHEEgRxDIEQRyBIEcQTQ6YqH7ewTCgVqGI/ikBAHlhgyc
axDojyCQIwjkCAI5gthC975V7oIb9Y4HG7ppHAmPLstbpfn5hm1oKFZJAecaBPojCORITVNqhbMl
+QzDS92I5/1GWUtG4zXebWgl+w3SqVFpJ1ZSlTa0q7bZjVcbu1NXP9cYhsN8l8kG+3HO+K8QntMI
Md/J5uVevwGlaMnf9OLGaJzG84oh0NgG6tRVjyPlBKWGGjzjPy4qjF1hT1CEvL4kUb3fUstewxqg
8bTSgKUG6tQ65xrVcH5Cg51aMhCWDIjqxg2SallDanC7iY03Qn1a2pqG6NQItZyq7/s3Vu4Z1dh4
76SKj7cpja9Bs9UInRqL9rKlbF9BYWr4vkRlg0miBhqwNRrfAO3aUfegoULoy0xqvTn2ebvr06tG
ydBsrHBj3BCNN9byxGE9OzW2ytegVh7OvDOcPMGcquGe5GfWb64JVe23TPecBjRW48s2qkE61afl
NCpGhl5u2I/Kwp/XNGxDw5/XqCs99Nj8JqsVOhmxWe8INO5nwciRxkAjrxUoz5EtEwk9v1UaWtjC
/I1tNVJjQzccuDYAgRxBIEcQyBEEcgSBHEFsdfjvffHLJRArcAS/WgKBcw0COYJAjiCQIwjkCAI5
gkCOIBAIRBn8P5DQb1/c1on/AAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-11-26 09:19:35 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASkAAAGSCAIAAAAw9qBjAAAS1UlEQVR42u3dv24lxRLH8SMhIQIH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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-10-29 16:12:37 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-10-29 16:12:37 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-10-29 16:12:37 -0400" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-21 13:53:51 -0400" MODIFIED_BY="[Empty name]">
<P>OVID EBM Reviews - Cochrane Central Register of Controlled Trials &lt;September 2014&gt;</P>
<P>1 exp enteral nutrition/ (1307)<BR/>2 (enter$ adj3 feed$).tw. (864)<BR/>3 (enter$ adj3 nutrit$).tw. (1837)<BR/>4 or/1-3 (2879)<BR/>5 exp Intubation, Gastrointestinal/ (527)<BR/>6 (nasoenteral$ or naso enteral$).tw. (16)<BR/>7 (esophag$ adj3 intubat$).tw. (64)<BR/>8 (oesophag$ adj3 intubat$).tw. (54)<BR/>9 (duoden$ adj3 intubat$).tw. (28)<BR/>10 (gastrointest$ adj3 intubat$).tw. (4)<BR/>11 (gastric adj3 intubat$).tw. (70)<BR/>12 (esophag$ adj3 catheter$).tw. (40)<BR/>13 (oesophag$ adj3 catheter$).tw. (18)<BR/>14 (duoden$ adj3 catheter$).tw. (6)<BR/>15 (stomach adj3 intubat$).tw. (12)<BR/>16 (stomach adj3 catheter$).tw. (7)<BR/>17 (gastrointest$ adj3 catheter$).tw. (3)<BR/>18 (gastric adj3 catheter$).tw. (19)<BR/>19 exp gastrointestinal motility/ (2442)<BR/>20 exp gastric emptying/ (1141)<BR/>21 (stomach adj3 emptying).tw. (97)<BR/>22 (gastric adj3 emptying).tw. (1870)<BR/>23 (gastro$ adj3 motili$).tw. (413)<BR/>24 (gastric adj3 motili$).tw. (306)<BR/>25 or/5-24 (4251)<BR/>26 exp metoclopramide/ (954)<BR/>27 (Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Dibertil or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclopramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid).tw. (1717)<BR/>28 or/26-27 (1783)<BR/>29 4 and 25 and 28 (22)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-10-21 13:53:25 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-12-10 06:18:48 -0500" MODIFIED_BY="Cathy Bennett">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-21 13:53:25 -0400" MODIFIED_BY="[Empty name]">
<P>Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) &lt;1946 to Present&gt;</P>
<P>1 randomized controlled trial.pt. (397350)<BR/>2 controlled clinical trial.pt. (90496)<BR/>3 randomized.ab. (316885)<BR/>4 placebo.ab. (162975)<BR/>5 drug therapy.fs. (1775294)<BR/>6 randomly.ab. (227206)<BR/>7 trial.ab. (330636)<BR/>8 groups.ab. (1429199)<BR/>9 or/1-8 (3509100)<BR/>10 exp animals/ not humans.sh. (4077582)<BR/>11 9 not 10 (3013932)<BR/>12 exp enteral nutrition/ (16146)<BR/>13 (enter$ adj3 feed$).tw. (5972)<BR/>14 (enter$ adj3 nutrit$).tw. (6942)<BR/>15 or/12-14 (20878)<BR/>16 exp Intubation, Gastrointestinal/ (8571)<BR/>17 (nasoenteral$ or naso enteral$).tw. (139)<BR/>18 (esophag$ adj3 intubat$).tw. (601)<BR/>19 (oesophag$ adj3 intubat$).tw. (242)<BR/>20 (duoden$ adj3 intubat$).tw. (382)<BR/>21 (gastrointest$ adj3 intubat$).tw. (52)<BR/>22 (gastric adj3 intubat$).tw. (984)<BR/>23 (esophag$ adj3 catheter$).tw. (376)<BR/>24 (oesophag$ adj3 catheter$).tw. (100)<BR/>25 (duoden$ adj3 catheter$).tw. (260)<BR/>26 (stomach adj3 intubat$).tw. (120)<BR/>27 (stomach adj3 catheter$).tw. (84)<BR/>28 (gastrointest$ adj3 catheter$).tw. (43)<BR/>29 (gastric adj3 catheter$).tw. (259)<BR/>30 exp gastrointestinal motility/ (33836)<BR/>31 exp gastric emptying/ (9078)<BR/>32 (stomach adj3 emptying).tw. (442)<BR/>33 (gastric adj3 emptying).tw. (10373)<BR/>34 (gastro$ adj3 motili$).tw. (4222)<BR/>35 (gastric adj3 motili$).tw. (2905)<BR/>36 or/16-35 (50241)<BR/>37 exp metoclopramide/ (4635)<BR/>38 (Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Dibertil or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclopramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid).tw. (5631)<BR/>39 or/37-38 (6628)<BR/>40 15 and 36 and 39 (63)<BR/>41 11 and 40 (39)<BR/>42 limit 41 to ed=20080101-20141021 (13)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-10-29 16:09:09 -0400" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-10-29 16:09:09 -0400" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-21 13:52:48 -0400" MODIFIED_BY="[Empty name]">
<P>1996 to 2014 Week 42</P>
<P>1 Clinical trial/ (687540)<BR/>2 Randomized controlled trial/ (306414)<BR/>3 Randomization/ (55320)<BR/>4 Single blind procedure/ (17566)<BR/>5 Double blind procedure/ (91805)<BR/>6 Crossover procedure/ (36116)<BR/>7 Placebo/ (200584)<BR/>8 Randomi?ed controlled trial$.tw. (101060)<BR/>9 Rct.tw. (14607)<BR/>10 Random allocation.tw. (1055)<BR/>11 Randomly allocated.tw. (17036)<BR/>12 Allocated randomly.tw. (1316)<BR/>13 (allocated adj2 random).tw. (286)<BR/>14 Single blind$.tw. (11523)<BR/>15 Double blind$.tw. (102885)<BR/>16 ((treble or triple) adj blind$).tw. (337)<BR/>17 Placebo$.tw. (158223)<BR/>18 Prospective study/ (242685)<BR/>19 or/1-18 (1162726)<BR/>20 Case study/ (25629)<BR/>21 Case report.tw. (196639)<BR/>22 Abstract report/ or letter/ (563718)<BR/>23 or/20-22 (780796)<BR/>24 19 not 23 (1132564)<BR/>25 exp enteral nutrition/ (15911)<BR/>26 (enter$ adj3 feed$).tw. (5886)<BR/>27 (enter$ adj3 nutrit$).tw. (8814)<BR/>28 or/25-27 (19640)<BR/>29 exp Intubation, Gastrointestinal/ (2924)<BR/>30 (nasoenteral$ or naso enteral$).tw. (117)<BR/>31 (esophag$ adj3 intubat$).tw. (449)<BR/>32 (oesophag$ adj3 intubat$).tw. (158)<BR/>33 (duoden$ adj3 intubat$).tw. (96)<BR/>34 (gastrointest$ adj3 intubat$).tw. (21)<BR/>35 (gastric adj3 intubat$).tw. (440)<BR/>36 (esophag$ adj3 catheter$).tw. (362)<BR/>37 (oesophag$ adj3 catheter$).tw. (91)<BR/>38 (duoden$ adj3 catheter$).tw. (134)<BR/>39 (stomach adj3 intubat$).tw. (58)<BR/>40 (stomach adj3 catheter$).tw. (46)<BR/>41 (gastrointest$ adj3 catheter$).tw. (36)<BR/>42 (gastric adj3 catheter$).tw. (224)<BR/>43 exp gastrointestinal motility/ (14371)<BR/>44 exp gastric emptying/ (10625)<BR/>45 (stomach adj3 emptying).tw. (230)<BR/>46 (gastric adj3 emptying).tw. (8625)<BR/>47 (gastro$ adj3 motili$).tw. (3722)<BR/>48 (gastric adj3 motili$).tw. (2146)<BR/>49 or/29-48 (29479)<BR/>50 exp metoclopramide/ (12043)<BR/>51 (Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Dibertil or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclopramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid).tw. (3489)<BR/>52 or/50-51 (12282)<BR/>53 28 and 49 and 52 (154)<BR/>54 24 and 53 (60)<BR/>55 limit 54 to em=200801-201442 (22)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-10-21 14:01:36 -0400" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-10-21 13:59:15 -0400" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-21 14:01:36 -0400" MODIFIED_BY="[Empty name]">
<P>(tw:(Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Dibertil or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclopramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid)) AND (year_cluster:(2008-2014))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in quantitative synthesis (meta-analysis). No new studies included in 2014 update&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;19 full-text articles (obtained previously) assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;58 new records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;58 additional records identified through database searching in October 2014&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;19 records previously identified and included or excluded in this review&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;58 new records excluded or discarded (did not fit inclusion criteria)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;15 full-text articles excluded, with reasons provided&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>